3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Endocrine
1
Conditions
Neoplasms
3
Osteosarcoma
2
Triple Negative Breast Neoplasms
1
Sarcoma, Clear Cell
1
Sarcoma
1
Rhabdomyosarcoma
1
Pathologic Complete Response
1
Ovarian Carcinosarcoma
1
Neuroblastoma
1
Neoplasm Metastasis
1
Melanoma
1
Hodgkin Disease
1
Hepatoblastoma
1
Hemangiosarcoma
1
Glioblastoma
1
Fibrolamellar hepatocellular carcinoma
1
Ependymoma
1
Diffuse Intrinsic Pontine Glioma
1
Carcinoma, Neuroendocrine
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Adrenocortical Carcinoma
1
Interventions
Doxorubicin
142
Ifosfamide
85
Radiotherapy
82
Cyclophosphamide
72
Gemcitabine
63
Filgrastim
54
pembrolizumab
43
pazopanib
40
Etoposide
39
Docetaxel
39
Vincristine
37
Trabectedin
37
Cisplatin
35
Nivolumab
32
Magnetic Resonance Spectroscopy
26
Irinotecan
26
Carboplatin
25
Surgical Procedures, Operative
24
Temozolomide
23
Radiation
22
Ipilimumab
22
Bevacizumab
20
Blood Specimen Collection
19
Granulocyte Colony-Stimulating Factor
18
Biopsy
18
eribulin
17
anlotinib
17
Sirolimus
17
Mesna
17
Melphalan
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
dostarlimab
×
Sarcoma
×
Clear all
NCT06333314
2025-12-02
Pan-MSI-ACSE
UNICANCER
Phase 2
Recruiting
120 enrolled